African Swine Fever Virus (ASFV) infection poses a serious threat to the global pig industry. It is listed as a reportableanimal disease by the World Organization for Animal Healthandcategorized as a Class Azoonosis byChinese government. There is an urgent need to develop a safe and effective vaccine for the prevention and control of ASFV.
Scientists from Guangzhou Institutesof Biomedicine and Health (GIBH) of Chinese Academy of Sciences and Guangzhou nBiomed Ltd. jointly developed a novel adenovirus-vectored ASFV (Ad2-ASFV) vaccine and vaccination regimen, which ishighly effective in protecting farmed pigs against ASFV strains.
Thestudy waspublished online inEmerging Microbes & Infections.
Scientists screened nine different types of adenovirus vectors and found that human type 2 replication-defective adenoviruses can efficiently deliver genes into pig-derived cells. Based on this vector, they constructedaAd2-ASFVvaccine delivering multiple antigens.
Mice and swine,vaccinatedwith the Ad2-ASFV vaccinethroughsimultaneous intramuscular and intranasal administration,exhibitedstrongsystemic antibody, cellular and mucosal immune responses against AFSV.Moreover, this vaccine provided complete protection for field pigs against circulating ASFV, whereas unvaccinated pigs were all infected with ASFV (Fig. 1).
Notably, the Ad2-ASFV vaccine demonstrated good safety. No adverse reactions were observed after vaccination.
This study shedslight on a new generation of safe and effective ASFV vaccines and suggests that inducing mucosal immunity can be a new direction for the development of ASFV vaccines.
Fig. 1TheAd2-ASFVvaccinerobustly elicitedspecific antibody, cellular,and mucosal immune responses in pigs and providedcomplete protection againstcirculatingASFVstrain infarmedpigs.（Image by GIBH）
Contact:
CHEN Ling, Ph.D., Principal Investigator;
LI Pingchao, Ph.D.
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Guangzhou, China, 510530
Email: chen_ling@gibh.ac.cn; li_pingchao@gibh.ac.cn
download：